Abstract
Background and Objectives: Pancreatic cancer is a highly aggressive malignancy with poor prognosis. Surgery is the only
curative treatment, but it carries a significant risk of morbidity. The role of preoperative EUS-guided biopsy (EUS-B) in up-front resectable patients has been a matter of debate, with some centers strongly advocating its use, whereas others limit it to indeterminate cases.
We aimed to examine whether preoperative EUS–guided biopsy (EUS-B) has an impact on overall survival (OS) using nationwide data.
Methods: The data of patients who underwent curatively intended surgical resection for pancreatic cancer were retrieved from the
prospectively maintained national Danish Pancreatic Cancer Group database. Associations between preoperative EUS-B and survival
were evaluated using Kaplan-Meier plots and univariable and multivariable Cox proportional hazards models. OS was examined in the
overall cohort and in a propensity score–matched subgroup, where EUS-B cases were matched to controls in a 1:2 ratio.
Results: Between 2011 and 2023, 1889 patients who underwent surgery for pancreatic cancer constituted the overall cohort. The
mean age was 67.4 (SD, 9.1) years, and 53.5% were male. The median overall survival was 28.5 months in the EUS-B group compared
to 26.7 months in the non–EUS-B group (HR, 1.07; 95% CI, 0.91–1.26; P = 0.411). In the propensity score–matched subgroup
(n = 582), the median survival time was 28.6 months (EUS-B group) and 24.7 months (non–EUS-B group; HR, 1.04; 95% CI,
0.84–1.29; P = 0.691).
Conclusions: Preoperative EUS-B did not influence survival in patients with pancreatic cancer in this nationwide retrospective study.
curative treatment, but it carries a significant risk of morbidity. The role of preoperative EUS-guided biopsy (EUS-B) in up-front resectable patients has been a matter of debate, with some centers strongly advocating its use, whereas others limit it to indeterminate cases.
We aimed to examine whether preoperative EUS–guided biopsy (EUS-B) has an impact on overall survival (OS) using nationwide data.
Methods: The data of patients who underwent curatively intended surgical resection for pancreatic cancer were retrieved from the
prospectively maintained national Danish Pancreatic Cancer Group database. Associations between preoperative EUS-B and survival
were evaluated using Kaplan-Meier plots and univariable and multivariable Cox proportional hazards models. OS was examined in the
overall cohort and in a propensity score–matched subgroup, where EUS-B cases were matched to controls in a 1:2 ratio.
Results: Between 2011 and 2023, 1889 patients who underwent surgery for pancreatic cancer constituted the overall cohort. The
mean age was 67.4 (SD, 9.1) years, and 53.5% were male. The median overall survival was 28.5 months in the EUS-B group compared
to 26.7 months in the non–EUS-B group (HR, 1.07; 95% CI, 0.91–1.26; P = 0.411). In the propensity score–matched subgroup
(n = 582), the median survival time was 28.6 months (EUS-B group) and 24.7 months (non–EUS-B group; HR, 1.04; 95% CI,
0.84–1.29; P = 0.691).
Conclusions: Preoperative EUS-B did not influence survival in patients with pancreatic cancer in this nationwide retrospective study.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Endoscopic Ultrasound |
| Vol/bind | 14 |
| Udgave nummer | 6 |
| Sider (fra-til) | 328-333 |
| ISSN | 2303-9027 |
| DOI | |
| Status | Udgivet - 2025 |